Magazine Article | February 1, 2021

Companies To Watch: Akero Therapeutics

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

Akero Therapeutics is developing drugs for metabolic diseases and has a weekly dosed compound, efruxifermin (EFX), heading for a Phase 2b/3 adaptive clinical trial for treating the common liver disease, NASH (non-alcoholic steatohepatitis). Originally licensed from Amgen, EFX mimics fibroblast growth factor 21 (FGF21) to reduce liver fat, inflammation, and fibrosis. Because FGF21 regulates many metabolic pathways and cellular processes, the company aims to explore the potential for EFX in other therapeutic areas.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: